RLYB
Another day, another fairness fight
Rallybio is now dealing with a shareholder investigation from Ademi LLP, which says it’s looking into whether the biotech is getting a fair price in its recently announced transaction with Avenzo Therapeutics. In plain English: somebody’s asking whether Rallybio shareholders are getting a deal that passes the sniff test.
Why investors should care
This kind of headline doesn’t automatically kill a deal, but it does crank up the drama. Once lawyers start circling, you can get more disclosure pressure, more noise around the transaction terms, and a little more uncertainty hanging over the stock like a storm cloud at a backyard BBQ.
What’s at stake
- The investigation centers on possible breaches of fiduciary duty and other legal issues.
- The target is Rallybio’s announced transaction with Avenzo Therapeutics.
- The market usually treats these alerts as a sign to expect more friction before anything gets cleanly wrapped up.
Big picture: even when the underlying deal goes through, shareholder investigations can keep investors on edge and put a spotlight on whether management really squeezed out the best possible price.